Filtered By:
Specialty: Cancer & Oncology
This page shows you your search results in order of date. This is page number 10.
Order by Relevance | Date
Total 124123 results found since Jan 2013.
PD-1 blockade induces reactivation of non-productive T cell responses characterized by NF-kB signaling in patients with pancreatic cancer
CONCLUSIONS: Cytotoxic T cells in the blood of PDAC patients remain sensitive to reinvigoration by PD-1 blockade and some have tumor-recognizing potential. Although these T cells proliferate and have a signature of IFN exposure, they also upregulate NF-κB signaling, which potentially counteracts the beneficial effects of anti-PD-1 reinvigoration and marks these T cells as non-productive contributors to anti-tumor immunity.PMID:37733830 | DOI:10.1158/1078-0432.CCR-23-1444
Source: Clinical Cancer Research - September 21, 2023 Category: Cancer & Oncology Authors: Lestat R Ali Patrick J Lenehan Victoire Cardot-Ruffino Andressa Dias Costa Matthew H G Katz Todd W Bauer Jonathan A Nowak Brian M Wolpin Thomas A Abrams Anuj Patel Thomas E Clancy Jiping Wang Joseph D Mancias Matthew J Reilley Chee-Chee H Stucky Tanios S Source Type: research
PERK Inhibition by HC-5404 Sensitizes Renal Cell Carcinoma Tumor Models to Antiangiogenic Tyrosine Kinase Inhibitors
CONCLUSIONS: By disrupting an adaptive stress response evoked by VEGFR-TKIs, HC-5404 presents a clinical opportunity to improve the antitumor effects of well-established standard of care therapies in RCC.PMID:37733811 | DOI:10.1158/1078-0432.CCR-23-1182
Source: Clinical Cancer Research - September 21, 2023 Category: Cancer & Oncology Authors: Michael E Stokes Veronica Calvo Sho Fujisawa Crissy Dudgeon Sharon Huang Nupur Ballal Leyi Shen Jennifer Gasparek Matthew Betzenhauser Simon J Taylor Kirk A Staschke Alan C Rigby Mark J Mulvihill Nandita Bose Eric S Lightcap David Surguladze Source Type: research
Differential benefit of metronomic chemotherapy among triple negative breast cancer subtypes treated in the IBCSG Trial 22-00
CONCLUSIONS: Our results show a differential benefit of low-dose CM therapy across different TNBC subtypes. Low-dose CM therapy could be considered as a potential immunomodulatory strategy for TNBC tumors with IM subtype in the early-disease setting.PMID:37733800 | DOI:10.1158/1078-0432.CCR-23-1267
Source: Clinical Cancer Research - September 21, 2023 Category: Cancer & Oncology Authors: Andrea Joaquin Garcia Mattia Rediti David Venet Samira Majjaj Roswitha Kammler Elisabetta Munzone Lorenzo Gianni Beat Th ürlimann Istv án Láng Marco Colleoni Sherene Loi Giuseppe Viale Meredith M Regan Laurence Buisseret Fran çoise Rothé Christos Sot Source Type: research
ATM mutations associate with distinct co-mutational patterns and therapeutic vulnerabilities in NSCLC
CONCLUSIONS: ATM mutations define a distinct subset of NSCLC associated with KRAS mutations, increased TMB, decreased TP53 and EGFR co-occurrence, and potential increased sensitivity to ICIs in the context of DNA-damaging chemotherapy.PMID:37733794 | DOI:10.1158/1078-0432.CCR-23-1122
Source: Clinical Cancer Research - September 21, 2023 Category: Cancer & Oncology Authors: Natalie I Vokes Ana Galan Cobo Margarita Fernandez-Chas David Molkentine Santiago Trevi ño Vitaly Druker Yu Qian Sonia Patel Stephanie Schmidt Lingzhi Hong Jeff Lewis Waree Rinsurongkawong Vadeerat Rinsurongkawong J Jack Lee Marcelo V Negrao Don L Gibbon Source Type: research
Near-infrared spectral tomography for predicting residual cancer burden during early stage neoadjuvant chemotherapy for breast cancer
CONCLUSION: NIRST holds promise as a potential clinical tool that can be seamlessly integrated into existing clinical workflow within the infusion suite. By providing early assessment of RCB, NIRST has potential to improve breast cancer patient management strategies.PMID:37733788 | DOI:10.1158/1078-0432.CCR-23-1593
Source: Clinical Cancer Research - September 21, 2023 Category: Cancer & Oncology Authors: Xu Cao Kristen E Muller Mary D Chamberlin Jiang Gui Peter A Kaufman Gary N Schwartz Roberta M DiFlorio-Alexander Brian W Pogue Keith D Paulsen Shudong Jiang Source Type: research
ASO Author Reflections: Can Nodal Features Improve Treatment Response Prediction in Esophageal Cancer?
Ann Surg Oncol. 2023 Sep 20. doi: 10.1245/s10434-023-14299-1. Online ahead of print.NO ABSTRACTPMID:37731144 | DOI:10.1245/s10434-023-14299-1
Source: Ann Oncol - September 21, 2023 Category: Cancer & Oncology Authors: Kunwei Li Shuaitong Zhang Hong Shan Source Type: research
Personalized Medicine's Coming of Age: One Drug, One Patient
Clin Cancer Res. 2023 Sep 21. doi: 10.1158/1078-0432.CCR-23-2194. Online ahead of print.ABSTRACTA dendritic cell/myeloma fusion vaccine, given with lenalidomide and GM-CSF, did not result in a statistically significant increase in CR rates at 1-year post-transplant but was associated with a significant increase in circulating multiple myeloma-reactive lymphocytes indicative of tumor-specific immunity.PMID:37733765 | DOI:10.1158/1078-0432.CCR-23-2194
Source: Clinical Cancer Research - September 21, 2023 Category: Cancer & Oncology Authors: Muzaffar H Qazilbash Larry W Kwak Source Type: research
10-Patient Trial: Remarkable Responses in Pediatric Cancers
Clin Cancer Res. 2023 Sep 21. doi: 10.1158/1078-0432.CCR-23-2232. Online ahead of print.ABSTRACTA clinical trial of Nivolumab in 10 pediatric cancer patients with high tumor mutational burden demonstrated complete responses in 50% of patients. This result recapitulates multiple clinical trial results in high mutation burden adult cancers and may redefine best practice in the setting of germline DNA mismatch repair-based susceptibility.PMID:37733329 | DOI:10.1158/1078-0432.CCR-23-2232
Source: Clinical Cancer Research - September 21, 2023 Category: Cancer & Oncology Authors: Elaine R Mardis Source Type: research
AACR Cancer Centers Alliance: Fostering Collaboration and Innovation to Advance Lifesaving Scientific Discoveries for Patients
Clin Cancer Res. 2023 Sep 13:OF1-OF3. doi: 10.1158/1078-0432.CCR-23-2625. Online ahead of print.ABSTRACTBasic and clinical cancer research discoveries stemming from the nation's cancer centers have markedly improved outcomes for many cancer patients. Despite this forward momentum in our progress against this complex disease, cancer in all its forms remains a major public health challenge that touches the lives of nearly every American, either directly or indirectly. The newly formed AACR Cancer Centers Alliance will accelerate the pace of discovery by providing an ongoing mechanism for transferring new knowledge, sharing r...
Source: Clinical Cancer Research - September 21, 2023 Category: Cancer & Oncology Authors: Carlos L Arteaga John L Cleveland Margaret Foti Ruben A Mesa Louis M Weiner Cheryl L Willman David A Tuveson Source Type: research
Deuterium Magnetic Resonance Imaging Using Deuterated Water-Induced 2H-Tissue Labeling Allows Monitoring Cancer Treatment at Clinical Field Strength
CONCLUSIONS: Deuterium MRI at 1.5T proved feasibility to track 2H distribution throughout mouse tissues during D2O administration and revealed a higher 2H accumulation in the tumor xenografts. This research demonstrated a promising successful method for preliminary assessment of radiotherapy and chemotherapy of cancer.PMID:37732903 | DOI:10.1158/1078-0432.CCR-23-1635
Source: Clinical Cancer Research - September 21, 2023 Category: Cancer & Oncology Authors: Hirofumi Asano Abdelazim Elsayed Elhelaly Fuminori Hyodo Ryota Iwasaki Yoshifumi Noda Hiroki Kato Koki Ichihashi Hiroyuki Tomita Masaharu Murata Takashi Mori Masayuki Matsuo Source Type: research
Stereotactic Body Radiation Therapy and Abiraterone Acetate for Patients Affected by Oligometastatic Castrate-Resistant Prostate Cancer: A Randomized Phase II Trial (ARTO)
CONCLUSION: The trial reached its primary end point of biochemical control and PFS, suggesting a clinical advantage for SBRT in addition to first-line AAP treatment in patients with metastatic castration-resistant prostate cancer.PMID:37733977 | DOI:10.1200/JCO.23.00985
Source: Clinical Prostate Cancer - September 21, 2023 Category: Cancer & Oncology Authors: Giulio Francolini Andrea Gaetano Allegra Beatrice Detti Vanessa Di Cataldo Saverio Caini Alessio Bruni Gianluca Ingrosso Rolando Maria D'Angelillo Anna Rita Alitto Matteo Augugliaro Luca Triggiani Silvana Parisi Gaetano Facchini Marco Banini Gabriele Simo Source Type: research
Aggressive variant prostate cancer: A case report and literature review
CONCLUSION: We should reach consensus definitions of the AVPC and other androgen receptor-independent subtypes of PCA and develop new biomarkers to identify groups of high-risk variants. It is crucial to complete a puncture biopsy of the tumor or metastatic lesion as soon as possible in patients with advanced PCA who exhibit clinical features such as low Prostate-specific antigen levels, high carcinoembryonic antigen levels, and insensitivity to hormones to determine the pathological histological type and to create a more aggressive monitoring and treatment regimens.PMID:37731555 | PMC:PMC10507546 | DOI:10.12998/wjcc.v11.i26.6213
Source: Clinical Prostate Cancer - September 21, 2023 Category: Cancer & Oncology Authors: Xiang-Tao Weng Wen-Li Lin Qi-Man Pan Tao-Fen Chen Si-Yi Li Chi-Ming Gu Source Type: research
Outcomes of Patients Treated With RCHOP With a PET-Adapted Approach for Consolidative Radiotherapy: A Retrospective Single-Center Study at the Royal Marsden Hospital
CONCLUSION: CRT may be omitted in patients with a negative end of treatment PET scans; however, careful observation may also obviate the need for CRT in PET positive patients.PMID:37734988 | DOI:10.1016/j.clml.2023.08.021
Source: Clinical Lymphoma and Myeloma - September 21, 2023 Category: Cancer & Oncology Authors: Su Li Bhupinder Sharma Siraj Yusuf Vasiliki Michalarea Mary Gleeson Laura Hickmott Andrew Wotherspoon Ayoma D Attygalle Katherine Vroobel Simon O'Connor Yong Du Andrea Kuhnl Sunil Iyengar Dima El-Sharkawi Ian Chau David Cunningham Source Type: research
A Novel Scoring Model of Deubiquitination Patterns Predicts Prognosis and Immunotherapeutic Response in Hepatocellular Carcinoma
In conclusion, our study revealed the crucial role of deubiquitination patterns in shaping TME complexity and diversity. A more personalized and effective antitumour immunotherapy strategy can be developed by utilizing the DUBscore model to identify deubiquitination patterns in individual HCC patients. Our findings also highlight that BRCC3 may serve as a potential therapeutic target in HCC and a predictive marker for immunotherapeutic response.PMID:37734237 | DOI:10.1016/j.tranon.2023.101789
Source: Translational Oncology - September 21, 2023 Category: Cancer & Oncology Authors: Jiahao Zhang Gefeng Wu Rui Peng Jun Cao Daoyuan Tu Jie Zhou Bingbing Su Shengjie Jin Guoqing Jiang Chi Zhang Dousheng Bai Source Type: research
Effectiveness and safety of REBACIN as a non-invasive intervention for persistent high-risk human papillomavirus infection: A real-world prospective multicenter cohort study
CONCLUSION: This study confirmed that REBACIN can effectively and safely eliminate persistent hrHPV infection, which the clearance rate of HPV16/18 is higher than that of HPV52/58, the clearance rate of single-type infection is higher than that of multiple-type infections, and the clearance rate in young patients is higher than that in elder patients, providing a guidance for REBACIN application in clearing hrHPV persistent infection in real-world settings.CLINICAL TRIAL REGISTRATION: Chinese Clinical Trial Registry Registration Number: ChiCTR1800015617 http://www.chictr.org.cn/showproj.aspx?proj=26529 Date of Registration...
Source: Gynecologic Oncology - September 21, 2023 Category: Cancer & Oncology Authors: Fei Chen Guo-Nan Zhang Wei Lei Shu-Guang Zhou Ying Zhang Lin Liu Ying Jia Rong-Kai Xie Xiu-Fang Tian Jie Guo Yue-Bo Yang Xue-Feng Wang Xiao-Mei Wu Qi-Jian Sun Xu Zhou Yang Lin You-Zhong Zhang Jun-Qi Ma Yu-Xiu Liu Yi-Fan Cheng Jian-Cui Chen Quan-Xin Qu Don Source Type: research
